 |
|
|
|
 |
|
|
|
| Article 1 to 10 out of 128
|
|
-
Novartis Menveo vaccine shows superior immune response against four types of meningitis disease in pivotal phase III trial
(07 May 2008)
First Phase III, head-to-head data show Menveo may offer greater protection for adolescents compared to Menactra
New Phase III data for Menveo® (MenACWY-CRM) show that the vaccine produced a greater immune response against meningococcal serogroups A, C, W-135 and Y in adolescents 11-18 years of age compared to Menactra®. Infection with any of these four ......
-
Galapagos and Allergan enter drug discovery collaboration
(07 May 2008)
Galapagos NV announced today that Galapagos' service division, BioFocus DPI, will provide hit-finding services for multiple Allergan, Inc. targets. Total contract value for Galapagos could reach up to EUR1.3 million over the next 12 months, ......
-
A step forward in virology: Trojan horse of viruses revealed
(28 Apr 2008)
Viruses use various tricks and disguises to invade cells. ETH Zurich researchers have now discovered yet another strategy used by viruses: the vaccinia virus disguises itself as cell waste, triggers the formation of evaginations in cells and is ......
-
Actelion and Nippon Shinyaku enter into a license agreement on novel PAH compound
(24 Apr 2008)
Actelion Ltd and Nippon Shinyaku announced that the two companies have signed a license agreement on a novel orally available PGI2 receptor agonist NS-304 originally discovered and synthesized by Nippon Shinyaku for the treatment of pulmonary ......
-
QIAGEN Enables Efforts to Eradicate Costly Cattle Disease
(23 Apr 2008)
Collaboration with Swiss laboratory Microsynth AG pioneers nucleic acid-based primary screening for Bovine Viral Diarrhea
QIAGEN N.V. announced that it has been awarded a contract by the Swiss life science company Microsynth AG to supply the molecular cador BVDV assays for detection of viruses causing Bovine Viral Diarrhea (BVD), one of the most widespread and ......
-
Actelion and Nippon Shinyaku enter into a license agreement on novel PAH compound
(23 Apr 2008)
Actelion Ltd and Nippon Shinyaku announced that the two companies have signed a license agreement on a novel orally available PGI2 receptor agonist NS-304 originally discovered and synthesized by Nippon Shinyaku for the treatment of pulmonary ......
-
Addex Appoints Laurent Massuyeau as Head of Business Development
(22 Apr 2008)
Addex Pharmaceuticals announced the appointment of Laurent Massuyeau as head of business development. Mr. Massuyeau joins Addex from Idenix Pharmaceuticals Inc., where he was executive director of European commercial operations. He brings to ......
-
Basilea opens new phase III study in special patient populations for its broad-spectrum antifungal isavuconazole
(16 Apr 2008)
Basilea Pharmaceutica Ltd. announced that it has opened an additional phase III study to evaluate the efficacy and safety of isavuconazole in treating serious and life-threatening invasive fungal infections. Isavuconazole's breadth of spectrum ......
-
ACZ885, a new biological drug in development, shows potential in treating serious life-long autoinflammatory diseases
(10 Apr 2008)
Human monoclonal antibody ACZ885 blocks interleukin 1ß, a key chemical messenger that causes inflammation and tissue destruction
New data demonstrate that ACZ885, a human monoclonal antibody in Phase III development, achieves long-lasting clinical remission in patients with genetic autoinflammatory diseases. The results indicate that ACZ885 could develop into a major ......
-
Decyphering the genetic program of the eye thanks to Balzan Prize Money
(25 Mar 2008)
The number of genes activated during eye development increases by up to 400 percent. That was one of the surprising results of a research project on the fruit fly carried out at the University of Basel (Switzerland). The project was financed to ......
|
|
|
Top